Animal Health Archives
Animal Pharmaceuticals
07/07/2026
Scaling Animal Health Programs Shouldn’t Mean Requalifying Your Supply Chain
Animal health programs tend to reveal their logistics weaknesses at the point of growth. A process that feels manageable when a therapy, vaccine, biologic, or reproductive material is moving between a limited number of familiar sites can become difficult to defend once the same program expands across facilities, regions, partners, or countries. The science may be ready to scale, but the operational framework often has to prove that it can scale with it.
Animal Pharmaceuticals
06/22/2026
Continuous Data Isn’t Optional for Animal Health
Animal health teams are moving more temperature-sensitive materials through more complex distribution networks than ever before. Vaccines, biotherapeutics, reproductive materials, diagnostics, and advanced therapies are all crossing longer distances and passing through more handoffs to reach a wider mix of farms, clinics, production facilities, and research sites. As that complexity grows, the standard for what logistics data must show is also changing. Programs are increasingly expected to document the actual condition and custody of materials throughout transit rather than rely on fragmented records assembled after delivery.
Animal Health
05/21/2026
Lane Qualification Reduces Risk Before Shipments Move
Animal health biopharmaceutical programs put pressure on logistics networks in ways that standard route planning doesn’t always capture. Vaccines may move in defined seasonal windows, while monoclonal antibodies (mAbs), cell-based therapies, biologics, and other sensitive materials may move through channels with different timing constraints. Some shipments are tied to manufacturing release, others are tied to clinical study schedules, and still others are fitting into regional disease control programs or veterinary network demand.
Managing the Cold Chain
05/12/2026
Why Risk Analysis and Lane Qualification Matter for Regulatory Confidence
As programs move from mid-phase into later development, expectations around compliance change in both scale and tone. Early filings may tolerate explanation, but later submissions expect evidence. Teams preparing for Phase II transitions, Phase III trials, or global commercialization begin to encounter a different level of scrutiny, where regulators are less interested in intent and more focused on whether processes behave consistently under real operating conditions.
Managing the Cold Chain
04/21/2026
Accelerate Your Trials Without Losing Control With an End-to-End Supply Chain Model
As programs shift from Phase I to Phase II, the workload starts to overlap in new ways. Sample volumes increase as more sites operate in parallel, and activities that once occurred in sequence now run at the same time. The work itself is largely the same, but keeping it coordinated requires more time and attention.
Animal Health
04/21/2026
Validated Shipping Systems are the Foundation of Risk-Mitigated Animal Health Logistics
Animal health logistics are entering a phase where variability is no longer tolerable. Vaccines, biologics, reproductive materials, and advanced therapies are sensitive to critical parameters like temperature and handling conditions, and as regulatory expectations continue to move toward tighter controls and clearer documentation, shipping has become so much more than a support function.
Managing the Cold Chain
04/09/2026
Where Innovation Is Moving the Advanced Therapies Supply Chain: A Q&A with Alison Pritchard
Following the Advanced Therapies Congress 2026, where Alison Pritchard delivered a keynote and participated in a panel discussion, she sat down for a brief conversation to expand on some of the themes that emerged during this year’s event. Alison’s perspective captures a few of the ideas she believes are shaping the next phase of supply chain design in advanced therapies.
Animal Health
03/19/2026
The Visibility and Traceability Animal Health Programs Need
Temperature-sensitive materials now move through animal health programs in far greater volumes, and that shift has raised the bar for how their transit needs to be documented. Teams responsible for oversight want documentation that reflects actual handling conditions from origin to delivery, with enough detail to support a clear assessment of risk. While the regulatory environment for animal health lags behind that for human health, programs are increasingly expected to provide records that reflect the actual conditions and custody of the material throughout transit.
Animal Health
02/20/2026